Search the Newsreel

Eikon Therapeutics (EIKN) reports $171.4M first-half loss and $531M cash

Eikon Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Eikon Therapeutics, Inc. 2Q 2026: Net income $(88.4)M, EPS $(1.63) — 10-Q Summary

Eikon Therapeutics, Inc. reported a net loss of $(88.4)M, or $(1.63) per share, for the second quarter of 2026, showing an improvement compared to the previous year. The company maintains $531.2M in cash and equivalents, sufficient for near-term operations for at least a year. …

Independent Committee Recommends Eikon Melanoma Trial Continue

Eikon Therapeutics (EIKN) announced that its adaptive Phase 2/3 TeLuRide-006 trial for EIK1001 in advanced melanoma will proceed with a single dose of 0.60 mg/m2 for all future EIK1001-treated patients. This decision follows a recommendation from an independent Data Monitoring Committee after a prespecified …

Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma

Eikon Therapeutics has selected 0.60 mg/m2 as the dose for EIK1001 in its TeLuRide-006 adaptive Phase 2/3 trial for advanced melanoma, based on a recommendation from an independent Data Monitoring Committee. The company aims to improve treatment outcomes for advanced melanoma patients by combining …

Press Release: Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to Its Scientific Advisory Board

Eikon Therapeutics has appointed Johnny Bennett, Ph.D., to its Scientific Advisory Board. Dr. Bennett brings extensive experience in drug discovery and development, particularly in oncology and immunology, which will support Eikon's mission to advance novel therapeutics. This appointment is expected to bolster the company's …

Eikon Therapeutics adds Merck chemistry head to advisory board

Eikon Therapeutics has appointed Johnny Bennett, Ph.D., Merck Research Laboratories' Vice President and Head of Discovery Chemistry, to its Scientific Advisory Board. This appointment strengthens the existing collaboration between Eikon and Merck, which includes Merck supplying KEYTRUDA for Eikon's clinical trials and participating in …

Eikon Therapeutics, Inc. Announces Appointment of Johnny Bennett, Ph.D. to Scientific Advisory Board

Eikon Therapeutics, Inc. has appointed Johnny Bennett, Ph.D. to its Scientific Advisory Board. Dr. Bennett, currently the Vice President and Head of Discovery Chemistry at Merck Research Laboratories, brings extensive experience in drug discovery, including the development of sugammadex. He joins a distinguished board …

FMR LLC reports 9.2% Eikon Therapeutics (EIKN) ownership on amended 13G

FMR LLC has filed an amended Schedule 13G/A, disclosing a 9.2% beneficial ownership stake in Eikon Therapeutics Inc. (EIKN), amounting to 4,993,906 shares of common stock. The filing indicates that FMR LLC holds sole voting power over 4,992,603 shares and sole dispositive power over …

Two Eikon Therapeutics, Inc. (Nasdaq: EIKN) directors step down

Eikon Therapeutics, Inc. (EIKN) reported that two board members, Leon Chen, Ph.D. and Joshua Wolfe, resigned from its Board of Directors, effective July 31, 2026. The company clarified that their resignations were not due to any disagreements regarding operations, policies, or practices. The report, …

Eikon Therapeutics, Inc.'s (NASDAQ:EIKN) Lock-Up Period Will Expire on August 4th

Eikon Therapeutics (NASDAQ:EIKN) is set to have its IPO lock-up period expire on August 4th, allowing major shareholders and insiders to sell their shares. The company's IPO in February involved 21.18 million shares at $18 each, raising approximately $381.2 million. Analyst sentiment is mixed, …

Eikon Therapeutics doses first patient in lung cancer trial

Eikon Therapeutics Inc. has announced the dosing of the first patient in TeLuRide-008, a Phase 2/3 study for its drug EIK1001 in combination with pembrolizumab and chemotherapy for treatment-naïve patients with stage 4 Non-Small Cell Lung Cancer (NSCLC). This global, multicenter, double-blind, placebo-controlled study …

Eikon Therapeutics, Inc. Revenue Breakdown – BX:EIKN

This article focuses on the revenue breakdown of Eikon Therapeutics, Inc. (BX:EIKN), as provided on TradingView. It details how users can analyze the company's financial overview, statements, statistics, dividends, earnings, and segment performance by source and country. The content highlights that financial data and …

Seven Eikon abstracts include lung and prostate cancer studies at ESMO

Eikon Therapeutics (Nasdaq: EIKN) announced that seven abstracts detailing progress across its oncology pipeline have been accepted for presentation at the 2026 European Society of Medical Oncology (ESMO) Congress. These abstracts include updated Phase 2 data for EIK1001 in non-small cell lung cancer, Phase …

Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress

Eikon Therapeutics announced that seven abstracts covering progress across its lead oncology programs have been accepted for presentation at the 2026 European Society of Medical Oncology (ESMO) Congress. These presentations will include updated data from ongoing trials for EIK1001, EIK1003, EIK1004, and initial safety …

Eikon Therapeutics Jumps 16.24%: Key Levels and What Lies Ahead for EIKN - Rounding Top

Eikon Therapeutics (EIKN) Slips 1.23% as Stock Tests Key Support at $9.13 - Retail Driven Moves

EIKN Q1 2026 Earnings: EPS Misses Estimates by 38.3%, Shares Slide 8.4% - Segment Revenue Breakdown

EIKN Q1 2026 Earnings: Pre-Revenue Biotech Misses EPS Estimates, Stock Slips - Debt Analysis Report

Eikon Therapeutics (EIKN) Earnings Date and Reports 2026

Eikon Therapeutics (EIKN) Stock Price, News & Analysis

What is the current Price Target and Forecast for Eikon Therapeutics, Inc. (EIKN)

Eikon Therapeutics, Inc (EIKN) Stock Price Today: $10.23

Eikon Therapeutics, Inc. (EIKN) Company Profile & Facts

Eikon Therapeutics (EIKN) Stock News & Updates

Eikon Therapeutics, Inc. (EIKN) stock price, news, quote and history